Article

Engineered stable, antibiotic-free, high-level protein expression in the probiotic chassis Escherichia coli Nissle 1917

2025-05-25

Abstract excerpt

The application of engineered live biotherapeutic products (LBPs) to secrete small molecules, peptides, or proteins to benefit a human or animal host, relies on heterologous protein expression. Key challenges in this area include expressing protein in a targeted location, the use of antibiotic-free platforms, and expressing recombinant proteins at titers capable of the desired therapeutic effect. In this study, we...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f2f3baa9-e5e0-5a9a-bc42-882ec18d8462
DOI: 10.22541/au.174816201.11324415/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Engineered stable, antibiotic-free, high-level protein expression in the probiotic chassis Escherichia coli Nissle 1917DOI 10.22541/au.174816201.11324415/v1Read

Construction of Probiotic Escherichia coli Nissle 1917 as a Next- Generation Expression Platform and Its Application in Therapeutic Protein ProductionSemantic proximity Read

Engineering Escherichia coli Nissle as safe chassis for delivery of therapeutic peptidesSemantic proximity Read

Enhancing the antibacterial function of probiotic Escherichia coli Nissle: when less is moreSemantic proximity Read

A Synthetic Protein Secretion System for Living Bacterial TherapeuticsSemantic proximity Read

So you want to express your protein in Escherichia coli ?Semantic proximity Read

Fusion tags for protein solubility, purification and immunogenicity in Escherichia coli: the novel Fh8 systemSemantic proximity Read

Production of antibodies and antibody fragments containing non-natural amino acids in Escherichia coliSemantic proximity Read

Analysis of a detoxified Escherichia coli strain for bacteriophage productionSemantic proximity Read

Use of Escherichia coli Nissle 1917 producing recombinant colicins for treatment of IBD patientsSemantic proximity Read

Engineering a novel probiotic toolkit in Escherichia coli Nissle1917 for sensing and mitigating gut inflammatory diseasesSemantic proximity Read

Engineering Lactococcus lactis as a multi-stress tolerant biosynthetic chassis by deleting the prophage-related fragment.Semantic proximity Read

Marker-Free Chromosomal Engineering of Lactococcus lactis for Streptococcus agalactiae Surface Immunogenic Protein Delivery: Toward Probiotic-Based Mucosal BiomedicineSemantic proximity Read